A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00297921
Recruitment Status : Withdrawn
First Posted : March 1, 2006
Last Update Posted : November 6, 2013
Information provided by:
Millennium Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Primary Completion Date : No date given
  Study Completion Date : No date given